Veracyte, Inc.
VCYT
Rankning i aktier
#4240
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aktiekurs
$46.01
Marknadsvärde
$3.70B
Förändring (1 dag)
-0.47%
Förändring (1 år)
32.39%
Land
US
Handel Veracyte, Inc. (VCYT)
Kategori
Healthcare
Aktiekurshistorik för Veracyte, Inc. (VCYT)
Högsta slutkurs: $44.58 den 2026-10-01
Lägsta slutkurs: $12.82 den 2013-10-01
Lägsta slutkurs: $12.82 den 2013-10-01
Aktiekurshistorik för Veracyte, Inc. från 2013 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | -2.87% |
| 2025 | 3.85% |
| 2024 | 55.02% |
| 2023 | 1.26% |
| 2022 | -33.63% |
| 2021 | -25.42% |
| 2020 | 88.25% |
| 2019 | 137.21% |
| 2018 | 87.23% |
| 2017 | -13.42% |
| 2016 | 5.54% |
| 2015 | -8.13% |
| 2014 | -43.76% |
| 2013 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $676.48 | 19.27% |
US
|
|
| $229.93 | 5.42% |
US
|
|
| $398.85 | 112.13% |
US
|
|
| $21.16 | 49.45% |
CN
|
|
| $174.35 | 19.52% |
US
|
